Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites –
BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites.
“This is an important milestone for the company as it expands our global footprint while providing access to those who can benefit from our cutting-edge early detection CRC test in these additional major international territories,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Dante has been an exceptional partner, and we look forward to continue working closely with them as they actively market and sell ColoAlert and also as they transition from processing samples at Mainz’s in-house facility, to their own wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) where they’ll offer localized service and support.”
Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing personalized preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.
“From our perspective, ColoAlert represents the first true step toward personalized medicine in colorectal cancer, and we are excited to leverage our expertise in genomic data to partner with Mainz in commercializing this important diagnostic tool,” said Andrea Riposati, Chief Executive Officer of Dante Genomics. “Through our partnership with Mainz, we will drive more informed healthcare decisions and empower patients with their genomic data.”
ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE-IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company’s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.
About Colorectal Cancer
Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late-stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US-based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.
About Mainz Biomed N.V.
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed’s product candidate portfolio includes PancAlert, an early-stage pancreatic cancer screening test based on Real-Time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.
For more information, please visitwww.mainzbiomed.com
For media enquiries, please contact firstname.lastname@example.org
For investor enquiries, please contact email@example.com
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.
Dante Genomics Contact:
VP of Investor Relations
+39 0862 191 0671
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nexstim NBS 5+ System Continues to Generate Interest in the US6.10.2022 11:00:00 CEST | Press release
Press release,Helsinki,6October2022 at12PM (EEST) Nexstim NBS 5+ System Continues to Generate Interest in the US Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that Drs. Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system. Marangell and Al Jurdi, both previously faculty at Baylor College of Medicine, founded Brain Health Consultants and TMS Center as a private outpatient program offering state of the art treatment for people with depression and related disorders. The NBS 5+ system, released in the United States in 2021, combines the capabilities of Nexstim’s NBS and NBT® systems. It thus enables the delivery of both diagnostic and therapeutic applications; diagnostic use meaning identifying the precise location and amount of stimulation required to active specific nerve cells for use across specialities such as neurosurgery, neuroradiology and psychiatry and therapeutic use referring to the treatment o
Huhtamaki publishes its Q3 2022 Interim Report on October 21, 20226.10.2022 09:00:00 CEST | Press release
HUHTAMÄKI OYJ PRESS RELEASE 6.10.2022 AT 10:00 Huhtamaki publishes its Q3 2022 Interim Report on October 21, 2022 Huhtamäki Oyj will publish its Q3 2022 Interim Report on Friday, October 21, 2022, approximately at 8:30 Finnish time (EEST). The release and related results presentation material will be available after publishing at www.huhtamaki.com/investors. Teleconference Huhtamaki will arrange a combined webcast and teleconference on the same day at 9:30 Finnish time. Huhtamaki´s President and CEO Charles Héaulmé and CFO Thomas Geust will present the results. The event will be followed by a Q&A session. The event will be held in English, it can be followed real-time at: https://huhtamaki.videosync.fi/2022-q3-results/ If you wish to ask questions, please dial one of the following numbers 5-10 minutes prior to the call start: Finland: +358 9 2319 5436 Sweden: +46 (0) 8 5051 0086 UK: +44 (0) 33 0551 0211 US: +1 646 843 4609 Participant Passcode: 0422950# An on-demand replay of the audio
Yara calls for urgent action to reduce Europe’s food dependency on Russia6.10.2022 08:31:11 CEST | Press release
Oslo, October 6, 2022: Yara calls on the European Union and national governments to act urgently and decisively to ensure Europe reduces, and not strengthens, its dependency on Russia for food and fertilizers. A strong European fertilizer industry is crucial not only for ensuring food security in Europe and globally but also for ensuring that Europe can continue to take the lead in the green transition. “It is imperative that the war on Ukraine does not destroy the work towards a net-zero future. It is unthinkable that we will reach the climate targets without a strong, green European industry. Instead of weakening the position of the European fertilizer industry, which is a frontrunner in decarbonization, we need massive, coordinated efforts to reach zero emissions, while at the same time reducing our dependencies on Russia,” says Svein Tore Holsether, President and Chief Executive Officer of Yara. Curtailed production in Europe reduces worldwide availability of fertilizers and has di
Chief Legal Officer Nassib Abou-Khalil to leave Nokia6.10.2022 08:00:00 CEST | Press release
Nokia Corporation Stock Exchange Release 6 October 2022 at 9:00 EEST Chief Legal Officer Nassib Abou-Khalil to leave Nokia Espoo, Finland – Nokia’s Chief Legal Officer, Nassib Abou-Khalil, has decided to leave Nokia and step down from its Group Leadership Team. A recruitment process will begin immediately for his successor. Nassib Abou-Khalil joined Nokia in 2014 and was appointed Chief Legal Officer in 2019. Before that role, he held various legal and compliance leadership positions in the company, including working as the general counsel for customer operations and leading the integration of the compliance programs of Alcatel-Lucent and Nokia. “This was a very difficult decision for me. However, after eight years with the company, it’s time for personal renewal and seeking new challenges externally. Whatever I have been able to realize – both as Nokia’s CLO and in our industry-leading inclusion and diversity work – has been possible only because of the support and encouragement I hav
Sampo plc’s share buybacks 05/10/20226.10.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 06/10/2022 at 08:30 am Sampo plc’s share buybacks 05/10/2022 On 05/10/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,23945.26AQEU39,17745.24CEUX12,60445.26TQEX73,85845.24XHELTOTAL139,87845.24 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 11,235,404 Sampo A shares representing 2.11 per cent of the total number of shares in Sampo plc. Details of